BRPI0810495A2 - difenil-di-hidro-imidazopiridinonas - Google Patents

difenil-di-hidro-imidazopiridinonas

Info

Publication number
BRPI0810495A2
BRPI0810495A2 BRPI0810495A BRPI0810495A BRPI0810495A2 BR PI0810495 A2 BRPI0810495 A2 BR PI0810495A2 BR PI0810495 A BRPI0810495 A BR PI0810495A BR PI0810495 A BRPI0810495 A BR PI0810495A BR PI0810495 A2 BRPI0810495 A2 BR PI0810495A2
Authority
BR
Brazil
Prior art keywords
dihydroimidazopyridinones
diphenyl
diphenyl dihydroimidazopyridinones
Prior art date
Application number
BRPI0810495A
Other languages
English (en)
Inventor
Thanh Vu Binh
Romyr Dominique
Qiao Qi
Alan Goodnow Robert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0810495A2 publication Critical patent/BRPI0810495A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0810495A 2007-04-12 2008-04-02 difenil-di-hidro-imidazopiridinonas BRPI0810495A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92311007P 2007-04-12 2007-04-12
PCT/EP2008/053903 WO2008125487A1 (en) 2007-04-12 2008-04-02 Diphenyl-dihydro-imidazopyridinones

Publications (1)

Publication Number Publication Date
BRPI0810495A2 true BRPI0810495A2 (pt) 2018-10-30

Family

ID=39478351

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810495A BRPI0810495A2 (pt) 2007-04-12 2008-04-02 difenil-di-hidro-imidazopiridinonas

Country Status (18)

Country Link
US (1) US7625895B2 (pt)
EP (1) EP2146986B1 (pt)
JP (1) JP2010523616A (pt)
KR (1) KR20090118116A (pt)
CN (1) CN101657449B (pt)
AR (1) AR066014A1 (pt)
AT (1) ATE514696T1 (pt)
AU (1) AU2008238062A1 (pt)
BR (1) BRPI0810495A2 (pt)
CA (1) CA2684008A1 (pt)
CL (1) CL2008001047A1 (pt)
ES (1) ES2367228T3 (pt)
IL (1) IL201021A0 (pt)
MX (1) MX2009011019A (pt)
PE (1) PE20090229A1 (pt)
RU (1) RU2009141522A (pt)
TW (1) TW200848033A (pt)
WO (1) WO2008125487A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102356085A (zh) 2009-01-16 2012-02-15 第一三共株式会社 具有脯氨酸环结构的咪唑并噻唑衍生物
JP2013510860A (ja) 2009-11-12 2013-03-28 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールmdm2アンタゴニスト
US10159669B2 (en) * 2010-03-02 2018-12-25 Ian H. Chan Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
CA2817585A1 (en) 2010-11-12 2012-05-18 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
ES2624808T3 (es) 2011-05-11 2017-07-17 The Regents Of The University Of Michigan Antagonistas de MDM2 espirooxindólicos
AU2012316055B2 (en) 2011-09-27 2016-05-12 Amgen Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
EP2935263B1 (en) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
CA2902856C (en) 2013-02-28 2021-02-16 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
WO2014151863A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
MA53572A1 (fr) 2013-06-10 2021-10-29 Amgen Inc Procédés de production et formes cristallines d'un inhibiteur mdm2
EA202092456A3 (ru) 2013-11-11 2021-09-30 Эмджен Инк. Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
SG11201606239UA (en) 2014-01-28 2016-08-30 Buck Inst For Res On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
AU2017246453A1 (en) 2016-04-06 2018-11-08 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
JP7037500B2 (ja) 2016-04-06 2022-03-16 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Mdm2タンパク質分解剤
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
MX2021003999A (es) 2018-10-08 2021-06-23 Univ Michigan Regents Moleculas de bajo peso molecular degradadoras de la proteina mdm2.
IL296451B2 (en) 2020-03-19 2026-05-01 Kymera Therapeutics Inc MDM2 joints and their uses
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358891A1 (fr) * 1976-07-22 1978-02-17 Yamanouchi Pharma Co Ltd Composes heterocycliques contenant un azote, utilise comme agents analgesiques et anti-inflammatoires
JPH02101065A (ja) 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
GB9704762D0 (en) * 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
GB2351082A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Synthesis of Cyclic Substituted Amidines
CN100486969C (zh) * 2001-12-18 2009-05-13 霍夫曼-拉罗奇有限公司 顺式-2,4,5-三苯基-咪唑啉及其在肿瘤治疗中的应用
PL370909A1 (en) * 2001-12-18 2005-05-30 F.Hoffmann-La Roche Ag Cis-imidazolines as mdm2 inhibitors
BRPI0411841A (pt) * 2003-06-17 2006-08-08 Hoffmann La Roche cis-2,4,5-triaril-imidazolinas
EP1753727B1 (en) 2004-05-18 2008-11-19 F.Hoffmann-La Roche Ag Novel cis-imidazolines
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
WO2007082805A1 (en) 2006-01-18 2007-07-26 F. Hoffmann-La Roche Ag Cis-4, 5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors
US8232298B2 (en) 2006-03-22 2012-07-31 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and P53

Also Published As

Publication number Publication date
WO2008125487A1 (en) 2008-10-23
KR20090118116A (ko) 2009-11-17
ATE514696T1 (de) 2011-07-15
CA2684008A1 (en) 2008-10-23
TW200848033A (en) 2008-12-16
IL201021A0 (en) 2010-05-17
ES2367228T3 (es) 2011-10-31
PE20090229A1 (es) 2009-03-27
AR066014A1 (es) 2009-07-15
RU2009141522A (ru) 2011-05-20
US20080255119A1 (en) 2008-10-16
CN101657449B (zh) 2012-06-06
EP2146986B1 (en) 2011-06-29
EP2146986A1 (en) 2010-01-27
AU2008238062A1 (en) 2008-10-23
CL2008001047A1 (es) 2009-01-16
JP2010523616A (ja) 2010-07-15
CN101657449A (zh) 2010-02-24
US7625895B2 (en) 2009-12-01
MX2009011019A (es) 2009-10-29

Similar Documents

Publication Publication Date Title
NO2016018I1 (no) Fluralaner
EP2131650A4 (en) PERFUSION REGULATION
EP2157090A4 (en) PYRAZINAMIDE COMPOUND
DE602008006301D1 (de) Koaxialnadelanordnung
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
PA8805201A1 (es) Piperidinas heteroaril-sustituidas
EP2160187A4 (en) SPIROINDALONE
DE602008004695D1 (de) Katalysatorträgerwabe
BRPI0812994A2 (pt) Microbiocidas
EP2151172A4 (en) LIGHT EMITTING DEVICE
EP2182216A4 (en) COMPRESSOR WITH ONE SCREW
DE602008005589D1 (de) Rliganden
FI20075057A0 (fi) Mäntähydraulimoottori
FI20075310A0 (fi) Aksiaalivuoinduktiosähkökone
DK2219566T3 (da) Ortoseled
EP2174732A4 (en) can seamer
FI20075115A0 (fi) Tuloilmayksikkö
EP2209817A4 (en) ANTIVIRAL COMPOSITIONS
FIU20080334U0 (fi) Nostosiirtokuljetusväline
ITBO20070745A1 (it) Minidumper
DE602007008359D1 (de) Hemdendbearbeitungsmaschine
NO20072673A (no) Notgripertrommel
AT504425B1 (de) Portioniersteuerung
FI20075119A0 (fi) Työalustajärjestelmä
ES1066101Y (es) Estuche

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2497 DE 13-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.